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zone or rosiglitazone for at least 4 consecutive months
between 1/1/1999 and 6/30/2000. RESULTS: All three
TZDs show similar prescription patterns, even though
both newer TZDs are approved as monotherapy and tro-
glitazone was not. The combination of TZD and sulfonyl-
urea occurred most commonly (troglitazone 28%, pio-
glitazone 26% and rosiglitazone 30%), followed by
monotherapy (troglitazone 20%, pioglitazone 23% and
rosiglitazone 23%). Combination with insulin (troglita-
zone 20%, pioglitazone 19% and rosiglitazone 16%)
ranked third for all. CONCLUSIONS: Our results sug-
gest that pioglitazone and rosiglitazone are prescribed in
a manner similar to troglitazone. This suggests that phy-
sicians should be particularly vigilant for drug interac-
tions between sulfonylureas and TZDs, as well as for ad-
ditive drug toxicities between from these drugs. This
analytic approach could be expanded to other drugs fre-
quently used in patients with type II diabetes, particularly
antihypertensives, drugs for congestive cardiac failure
and antihyperlipidemics.
PDB3
THE BURDEN OF ILLNESS OF DIABETES 
MELLITUS TYPE 2 IN GERMANY—
A PILOT STUDY
Tepe M1, Kilburg A2, Daniel D2, Kirchhoff D2, Rychlik R2
1Novartis Pharma GmbH, Nuremberg, Germany; 2Institute of 
Empirical Health Economics, Burscheid, Germany
OBJECTIVES: A study was performed to assess the costs
of diabetes mellitus type 2 considering costs for co-mor-
bidities and diabetes related complications in Germany.
The main objective of this cross-sectional study was to
describe the cost structure of the treatment of diabetes
mellitus type 2. The study focuses particularly on costs
for oral antidiabetic treatment. METHODS: The re-
source utilization of a population of 201 diabetes melli-
tus patients with type 2 diabetes was retrospectively doc-
umented over a period of 2 years in a cross-sectional
study. The documentation was performed by general
practitioners (GPs) and diabetologists across Germany.
Only direct costs were considered (perspective from stat-
utory health insurances). Subgroups were analysed con-
sidering diabetes related macro- and microvascular com-
plications. Costs were analysed taking the perspective of
the statutory health insurance into consideration. RE-
SULTS: Total costs of 201 patients suffering from diabe-
tes mellitus type 2 amounted to DM 1,477,061 over a pe-
riod of two years, which translates into DM 7,349 per
patient. Costs per year were DM 3,674 with a maximum
of DM 63,915. The largest cost-driving factor is the hos-
pitalisation representing 34.1 % of the total costs fol-
lowed by drug acquisition costs (20.4 %). Patients
treated with insulin cause the 3,5 times higher costs than
patients treated with oral drugs. The amount of costs also
correlates with the complication status and the duration
of diabetes. The lowest costs are caused by patients
treated with oral antidiabetic drugs and/or diet and with-
out complications. CONCLUSION: The highest costs
were caused by patients with a high complication status,
a long duration of diabetes and those treated with insu-
lin. This result emphasises the necessity of an early treat-
ment of diabetes mellitus type 2 preventing expensive di-
abetes related long-term complications e.g., myocardial
infarction, stroke, diabetic foot lesion or dialysis.
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BACKGROUND: Avandia (rosiglitazone) is a novel in-
sulin sensitizing agent. Compared with traditional thera-
pies for type 2 diabetes mellitus (T2DM), it is as effica-
cious in lowering glycemic parameters with the additional
benefit of improving insulin resistance (IR); both of these
are linked to increased risk of cardiovascular (CV)
events. An evaluation was conducted from a government
payer perspective to explore the potential cost-effective-
ness of Avandia compared with less costly generic agents,
glyburide and metformin. METHODS: A Markov model
was used to calculate direct medical costs and expected
survival. The discount rate was 5%. Long-term outcomes
were modeled based on clinical and epidemiologic studies
and the 10 year UKPDS data. Costs were obtained from
the manufacturer, literature, case costing and provincial
sources. The base case analysis considered a 70 y.o. male
with T2DM with a risk factor profile representative of
the UKPDS cohort. Further analyses of patients with
other combinations of CV co-morbidity were conducted
to examine the range of cost-effectiveness. RESULTS:
Avandia, compared to glyburide and metformin, is a po-
tentially attractive option. In the base case Avandia was
associated with the highest expected cost but also the
greatest survival ($7,781 and 6.254 years); metformin the
lowest cost ($3,655) and intermediate survival (6.181
years); glyburide was dominated by metformin ($3,667
and 6.1608 years); the incremental CE ratios for Avandia
were $56,888 and $44,237 per LY gained vs. metformin
and glyburide respectively. For patients with other clus-
ters of risk factors, the CE ratios ranged from $6,886/
LYG (4 additional CV risk factors) up to $59,947/LYG
(0 additional risks). The sensitivity analyses showed that
the base case results were robust. CONCLUSIONS:
While acknowledging the limitations of modeling tech-
niques, the results of this analysis suggest that Avandia,
which addresses both dysglycemia and IR, may be a cost-
effective alternative for T2DM compared to the conven-
tional therapies.
